Impact of magnesium supplementation on clinical outcome and disease progression of patients with diabetic nephropathy: a prospective randomized trial
Halawa N, Elsaid TW, El Wakeel LM, Shawki MA
Therapeutic advances in chronic disease · 8 citations
How it was studied
- Design
- Randomized controlled trial (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
Based on full-text disclosure statement.
Publication
- Published
- 2023-01-01 · Ther Adv Chronic Dis · vol. 14 · p. 20406223231214641
- Publisher
- SAGE Publishing
- Cited
- 10 citations · more than 77% of similar papers · 1.2× the field average
- References
- 49 works
- Access
- Open access (journal) · CC-BY-NC
- Research areas
- Magnesium in Health and Disease · Parathyroid Disorders and Treatments · Potassium and Related Disorders
- Keywords
- Medicine, Internal medicine, Regimen, Glycemic, Creatinine, Renal function, Randomized controlled trial, Tolerability, Gastroenterology, Lipid profile, Urology, Endocrinology, Adverse effect, Insulin, Cholesterol
4 authors
From EG
- Nihal HalawaAin Shams University
- Tamer Wahid ElsaidAin Shams University
- Lamia Mohamed El WakeelAin Shams University
- May Ahmed Shawki · correspondingAin Shams University
Abstract
Background
Magnesium (Mg) deficiency is closely linked with proteinuria.
Objectives
To assess the impact of oral Mg citrate supplementation on the clinical outcome of diabetic nephropathy (DN) patients.
Design
This was a prospective, randomized, controlled, open-label study.
Methods
Sixty DN patients were recruited from Nephrology and Endocrinology departments, Ain Shams University Hospitals, Cairo, Egypt. Patients were assigned by stratified randomization based on their Mg status, to either Mg citrate group, (n = 30), who received the standard regimen + oral Mg citrate 2.25 g/day or Control group, (n = 30), who received the standard regimen only. The primary endpoint was a change in urinary albumin to creatinine ratio (UACR) after 12 weeks. Secondary outcomes were insulin resistance, glycemic control, lipid profile, serum osteocalcin, quality of life (QoL) and Mg tolerability.
Results
Out of a total of 60 patients enrolled, only 54 patients (26 in Mg citrate group and 28 in the control group) completed the study. Groups were comparable at baseline. The UACR median percent reduction was significantly higher in the Mg citrate group (-6.87%) versus (-0.9%) in the Control group, p = 0.001. After 12 weeks, the estimated glomerular filtration rate significantly improved in the Mg citrate group versus Control group (p = 0.001). Comparable change was observed in glycemic indices. Lipid profile significantly improved in the Mg citrate group versus Control group (p = 0.001). Serum osteocalcin levels significantly declined in the Mg citrate group (p = 0.001) versus control group. Regarding QoL, the total score and all domains significantly improved in the Mg citrate group compared to control. The Mg supplement was tolerable with only mild reported side effects that required no intervention.
Conclusion
Oral Mg citrate supplementation improved microalbuminuria in DN patients. It also had favorable effects on serum osteocalcin, lipid profile and QoL with no reported major side effects.
Trial registration
ClinicalTrials.gov identifier: NCT03824379.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.